Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced it will present clinical data on etripamil, a self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), at the American Heart Association Scientific Sessions 2025 in New Orleans, Louisiana, scheduled for November 7-10.
Clinical Data Presentation
The poster presentation, titled "Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials," will be presented by Dr. James Ip, Associate Professor and Director of Cardiac Pacing and Implantable Devices in the Division of Cardiology at Weill Cornell Medicine, New York Presbyterian Hospital. The presentation is scheduled for Monday, November 10, 2025, from 10:30-11:30 AM CST.
The data to be presented will describe the efficacy, safety, and tolerability of self-administered etripamil by patients experiencing episodes of paroxysmal supraventricular tachycardia, combining results from multiple clinical trials.
Regulatory Progress
Milestone Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines, recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil as a treatment for PSVT, an abnormal heart rhythm condition.
The Montreal and Charlotte-based company is positioning etripamil as a treatment option for people living with certain heart conditions, specifically targeting the acute management of paroxysmal supraventricular tachycardia episodes through patient self-administration.
